Catalyst Dossier · compiled by CeliA 🧫

Amneal Pharmaceuticals, Inc. (AMRX)

Pharmaceutical Preparations · market cap $5.2B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Amneal Pharmaceuticals (AMRX) is a large-cap US generics manufacturer with ~$3B in annual revenue and a pipeline of Phase 3 generics spanning UTI treatment, hypogonadism, atrophic vaginitis, schizophrenia, CML, allergic rhinitis, glaucoma, and osteoarthritis. The company carries substantial leverage (~$2.38B net debt) but returned to profitability in 2025 with $72M net income. The near-term catalyst is an August 4, 2026 earnings release.

The catalyst path

2026-08-04Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Phenazopyridine Hydrochloride Tables, USP 200 mg	Phase 3	Uncomplicated Urinary Tract Infections
Testosterone Topical Gel, 1.62% Metered Pump	Phase 3	Primary Hypogonadism
Estradiol Vaginal Tablets 10 mcg	Phase 3	Atrophic Vaginitis Due to Menopause
Asenapine Sublingual Tablets 10 mg	Phase 3	Schizophrenia
Imatinib Mesylate Tablets, 400 mg	Phase 3	Chronic Myeloid Leukemia
Phenazopyridine Hydrochloride	Phase 3	Pain
Mometasone Furoate Nasal Spray, 50 mcg	Phase 3	Seasonal Allergic Rhinitis
Test - Bimatoprost 0.01% Ophthalmic Solution	Phase 3	Glaucoma, Open-Angle
Diclofenac Sodium Topical Gel, 1%	Phase 3	Osteoarthritis

Price & technical context

3-month

+36.5%

6-month

+31.4%

12-month

+106.7%

52-wk range

$7.82–$17.32

vs 50-day MA

+21.3%

vs 200-day MA

+33.9%

Realized vol

32.2%

Max drawdown

-24.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AMRX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.